ARRIVENT BIOPHARMA, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ARRIVENT BIOPHARMA, INC. (AVBP) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $6.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $6.67M, a 101.30% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.49M, a 141.52% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.72M, a 329.10% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.31M, a 332.25% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $12.52M, a 290.27% increase from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $3.21M, a 258.44% increase from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $895.00K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.67M 10-Q · filed 2026-08-12 | $12.15M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $5.49M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $12.52M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $3.72M 10-Q · filed 2025-11-10 | $7.03M derived: sum of 2 quarters · filed 2026-08-12 | $9.30M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $3.31M 10-Q · filed 2026-08-12 | $5.58M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $2.27M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $3.21M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $866.00K 10-Q · filed 2025-11-10 | $1.63M derived: sum of 2 quarters · filed 2025-11-10 | $2.26M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $766.00K 10-Q · filed 2025-11-10 | $1.39M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $625.00K 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $895.00K 10-K · filed 2025-03-03 | |||
| 2023-09-30 | $217.00K 10-Q · filed 2024-11-14 | $410.00K derived: sum of 2 quarters · filed 2024-11-14 | $576.00K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $193.00K 10-Q · filed 2024-11-14 | $359.00K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $166.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |